There has been a striking generational increase in life-threatening food allergies in Westernized societies. One hypothesis to explain this rising prevalence is that twenty-first century lifestyle practices, including misuse of antibiotics, dietary changes, and higher rates of Caesarean birth and formula feeding have altered intestinal bacterial communities; early-life alterations may be particularly detrimental.
BOSTON & SAN DIEGO–(BUSINESS WIRE)–ConsortiaTX, Inc. co-founder, Georg Gerber, M.D., Ph.D., has been awarded a 5-year, $1.5 million National Institutes of Health (NIH) grant to advance machine learning and software tools for longitudinal microbiome studies. ConsortiaTX has been developing and commercializing microbial therapies to prevent and treat human disease and allergies since its launch about a year and half ago.
Bio-therapeutics startup focused on developing therapies for food allergies BOSTON & SAN DIEGO–(BUSINESS WIRE)–ConsortiaTX, Inc., a bio-therapeutics startup developing and commercializing microbial therapies to prevent and treat human disease and allergies, has signed an agreement with Brigham and Women’s Hospital (BWH) and Boston Children’s Hospital for an exclusive, worldwide license for foundational intellectual property related […]